Acute bleeding management
›Immediate management bundle
›If active significant bleeding, NPO
›Aspiration risk reduction for possible emergent surgery
›Anesthesia notification
›IV access and resuscitation
›Crystalloid as bridge to blood products
›Early blood products for ongoing hemorrhage
›Rh immune globulin for Rh-negative
›300 micrograms IM within 72 hours for fetomaternal hemorrhage prophylaxis
›Additional dosing guided by fetal screen or Kleihauer-Betke if large hemorrhage
›Contraction management
›If uterine contractions with mild bleeding and preterm gestation, short-term tocolysis may be used selectively
›If ongoing heavy bleeding, avoid tocolysis and proceed toward delivery planning
Medications and transfusion protocols
›Antenatal corticosteroids
›Betamethasone IM 12 mg
›Second dose 12 mg IM in 24 hours
›Use when risk of preterm delivery within 7 days and gestational age criteria met
›Magnesium sulfate for fetal neuroprotection
›If anticipated preterm delivery at very preterm gestation per local protocol
›Loading dose 4 g IV over 20 to 30 minutes
›Maintenance 1 g/hour IV until delivery or time limit per protocol
›Tranexamic acid for postpartum hemorrhage context
›If postpartum hemorrhage occurs after delivery
›TXA 1 g IV over 10 minutes
›Second dose 1 g IV if bleeding continues after 30 minutes or restarts within 24 hours
›Packed red blood cells
›If symptomatic anemia or ongoing hemorrhage
›Transfusion target based on hemodynamics and ongoing loss
›Avoid delay for lab confirmation in unstable hemorrhage
›Massive transfusion protocol
›If ongoing life-threatening bleeding
›Balanced component therapy per institutional ratios
›Calcium replacement during large-volume transfusion
›Fibrinogen replacement
›If hypofibrinogenemia with active bleeding
›Cryoprecipitate dosing per institutional protocol
›Fibrinogen concentrate if available per institutional protocol
Delivery and operative planning
›Cesarean delivery planning
›Operative timing individualized
›Stable persistent previa planned cesarean in late preterm to early term window
›Earlier cesarean for recurrent bleeding or unstable course
›Surgical approach considerations
›Preoperative ultrasound for placental mapping
›Uterine incision away from placenta when feasible
›Postpartum hemorrhage preparation
›Uterotonics ready
›Uterine tamponade devices available
›Rapid access to blood products and hemorrhage cart
›Placenta accreta spectrum preparedness
›If suspected accreta, planned cesarean hysterectomy pathway
›Multidisciplinary team
›Blood bank coordination
›Critical care and neonatal support
›Placenta removal strategy
›Avoid forced placental separation if accreta suspected intraoperatively
›Proceed to hysterectomy plan if invasion suspected and bleeding risk high
Evidence levels and guideline mapping
›Evidence framing for ED and acute care
›No digital vaginal exam prior to ultrasound confirmation
›ACEP Level B equivalent practice standard extrapolated for harm avoidance
›Class I recommendation based on expert consensus
›Transvaginal ultrasound as diagnostic standard
›Class I recommendation based on guideline consensus
›Planned cesarean timing for stable previa
›Class IIa recommendation based on guideline consensus and cohort data
›Transfer to tertiary center for suspected accreta
›Class I recommendation based on outcomes and resource needs